State Department Eases Travel Advisories for Dozens of Countries
WEDNESDAY, June 9, 2021 -- COVID-19-related travel advisories for dozens of countries were eased Tuesday by the U.S. State Department.
It said that 58 countries and territories were moved from the Level 4 (Do Not Travel) category to Level 3 (Reconsider Travel) category, and another 27 nations were moved to the first two levels that recommend increased caution or normal precautions, The Washington Post reported.
Japan, France, Italy, Spain, Greece, Switzerland, Canada, and Mexico are among the countries no longer in the "Do Not Travel" category. Another 15 countries were moved to the moderate level, and 34 were placed in the low level, The Post reported.
The state department's move follows changes to the U.S. Centers for Disease Control and Prevention travel health notices in which 62 destinations were switched from the highest warning level to the second-highest. The CDC says Americans visiting countries in the second-highest level should be fully vaccinated, and unvaccinated people should avoid nonessential travel to those locations, The Post reported.
© 2021 HealthDay. All rights reserved.
Posted June 2021
Further Support and Information on COVID-19
Read this next
MONDAY, June 14, 2021 -- Individuals with inflammatory bowel disease (IBD) do not have an increased risk for adverse events (AEs) after the mRNA COVID-19 vaccination, according to...
MONDAY, June 14, 2021 -- There is a strong inverse correlation between convalescent plasma (CCP) use per admission and mortality for hospitalized COVID-19 patients, according to a...
MONDAY, June 14, 2021 -- Rates of severe stroke and stroke in younger patients are higher for stroke patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.